Cytokinetics Inc [CYTK] stock is trading at $52.22, up 0.38%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The CYTK shares have gain 4.73% over the last week, with a monthly amount glided 1.38%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Cytokinetics Inc [NASDAQ: CYTK] stock has seen the most recent analyst activity on November 08, 2024, when RBC Capital Mkts initiated its Outperform rating and assigned the stock a price target of $80. Previously, Goldman downgraded its rating to Neutral on August 13, 2024, and dropped its price target to $60. On January 24, 2024, downgrade downgraded it’s rating to Neutral and revised its price target to $92 on the stock. Morgan Stanley downgraded its rating to a Equal-Weight and increased its price target to $90 on January 05, 2024. Goldman initiated its recommendation with a Buy and recommended $50 as its price target on November 09, 2023. B. Riley Securities started tracking with a Buy rating for this stock on November 07, 2023, and assigned it a price target of $66. In a note dated August 15, 2023, SVB Securities initiated an Outperform rating and provided a target price of $58 on this stock.
Cytokinetics Inc [CYTK] stock has fluctuated between $30.68 and $110.25 over the past year. Currently, Wall Street analysts expect the stock to reach $83.23 within the next 12 months. Cytokinetics Inc [NASDAQ: CYTK] shares were valued at $52.22 at the most recent close of the market. An investor can expect a potential return of 59.38% based on the average CYTK price forecast.
Analyzing the CYTK fundamentals
Cytokinetics Inc [NASDAQ:CYTK] reported sales of 3.22M for the trailing twelve months, which represents a growth of 22.49%. Gross Profit Margin for this corporation currently stands at -28.72% with Operating Profit Margin at -162.98%, Pretax Profit Margin comes in at -179.06%, and Net Profit Margin reading is -179.06%. To continue investigating profitability, this company’s Return on Assets is posted at -0.4, Equity is 3.35 and Total Capital is -0.4. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -48.51.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 51.64 points at the first support level, and at 51.06 for the second support level. However, for the 1st resistance point, the stock is sitting at 52.82, and for the 2nd resistance point, it is at 53.42.
Ratios To Look Out For
For context, Cytokinetics Inc’s Current Ratio is 9.28. In addition, the Quick Ratio stands at 9.28 and the Cash Ratio stands at 0.43. Considering the valuation of this stock, the price to sales ratio is 1921.24.
Transactions by insiders
Recent insider trading involved Malik Fady Ibraham, EVP Research & Development, that happened on Nov 26 ’24 when 7300.0 shares were sold. Director, WIERENGA WENDALL completed a deal on Nov 25 ’24 to sell 742.0 shares. Meanwhile, Officer FADY MALIK bought 7300.0 shares on Nov 26 ’24.
